We performed a retrospective, comparative study to evaluate efficacy outcomes of empiric Elores (ceftriaxone/sulbactam/EDTA) therapy compared with the meropenem, imipenem and piperacillin/tazobactam in patients suspected of bacterial infections. Among the isolates which showed the presence of bacteria, around 36.0 % samples were of urine followed by sputum and blood which contributed to 15.7 % and 11.5 % respectively. Among the isolates, Escherichia coli (51.7 %) was found to be the most dominant pathogen followed by Klebsiella pneumoniae (29.5 %), Pseudomonas aeruginosa (15.0 %), Acinetobacter baumannii (2.3 %), and Proteus mirabilis (1.5 %). Higher susceptibility rates were achieved with Elores in comparison with piperacillin/tazobactam and meropenem. Susceptibility pattern for imipenem was almost same as that for Elores. Piperacillin/tazobactam resistance was high in all the tested pathogens ranging from 54.0 % (least in P. aeruginosa) to 100.0 % (highest in Proteus spp.) when compared to Elores to which low resistance was observed ranging from 19.0 % (least in P. aeruginosa) to 33.3 % (highest in A. baumannii) was observed. Overall, the results of the present study strongly advocate the superiority of Elores over piperacillin/tazobactam and meropenem and an equivalence to imipenem. Elores can be a very effective alternative to treat against the deadly multi drug resistant Gram negative bacteria, sparing penems as reserve drugs.
